Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Janus kinase (JAK) inhibitor, jacktinib, in systemic lupus erythematosus (SLE). This marks a significant milestone in the development of this innovative therapy for autoimmune diseases.
Drug Overview and Mechanism
Jacktinib is designed to improve immune-related inflammatory effects by blocking the signal transducer and activator of transcription (STAT) and JAK signaling pathways. This mechanism of action positions the drug to address significant unmet needs in the treatment of autoimmune conditions such as SLE.
Clinical Development and Future Outlook
Jacktinib is currently undergoing multiple clinical studies for various indications, including moderate- to high-risk myelofibrosis, myelofibrosis intolerant to ruxolitinib, severe alopecia areata, idiopathic pulmonary fibrosis, ankylosing spondylitis, moderate to severe plaque psoriasis, and moderate to severe atopic dermatitis. The drug has also obtained orphan drug designation status for myelofibrosis from the US FDA. The latest approval from the NMPA for an SLE clinical trial further expands the potential applications of jacktinib, highlighting its versatility and therapeutic potential.-Fineline Info & Tech
